BHIM payments app introduces MyUPI AI assistant for UPI support,
MyUPI, a new conversational AI assistant in the BHIM app, offers 24/7 support for UPI services, including transactions, complaints, and fraud awareness. Source
Read MoreMyUPI, a new conversational AI assistant in the BHIM app, offers 24/7 support for UPI services, including transactions, complaints, and fraud awareness. Source
Read MoreBank credit to industry accelerated sharply in August, while lending to services and agriculture also recorded strong year-on-year growth, according to RBI data. Non-food credit growth nearly doubled from a year earlier, pointing to broad-based credit expansion. Source
Read MoreWealthy.in Co-Founder Aditya Agarwal said the step-up approach works well because it allows investors to increase their savings and investments as their income grows. This helps them gradually raise their investment contribution instead of having to start with a large SIP amount. Source
Read MoreLemon Tree Hotels has opened its first property in Darjeeling, a 65-room Keys Prima hotel, expanding its operational presence in West Bengal to three properties. The group has three more properties in the state pipeline. Source
Read MoreZerodha Fund House launches an ETF tracking the Nifty Next 100 Index, expanding its passive fund offerings beyond the Nifty 50. The NFO is open until October 5. Source
Read MoreTop 10@10 — CNBC-TV18’s daily newsletter featuring the top 10 stories on markets, corporate updates, economic insights, and financial highlights — delivered at 10 pm Source
Read MoreNPCI clarifies: GST on UPI MDR won’t burden small merchants. Zero MDR for transactions under ₹2,000, no GST impact. Source
Read MoreIndia’s corporate boardrooms need more than one woman director. Leaders at CNBC-TV18’s Future Female Forward townhall call for 33% women representation to drive Source
Read MoreNew report by Capgemini Research Institute and LIMRA reveals consumers struggle with life insurance due to complex language, cost, and relevance. Source
Read MoreAurobindo Pharma’s Acrotech Biopharma has launched ADQUEY, a non-steroidal topical treatment for mild-to-moderate atopic dermatitis, in the US. The product enters a market estimated at around $1.3 billion for the 12 months ended July 2026, while Acrotech has established a dedicated dermatology business unit. Source
Read More